KPIs & Operating Metrics(New)
Growth Metrics

Abbott Laboratories (ABT) Receivables (2016 - 2026)

Abbott Laboratories' Receivables history spans 18 years, with the latest figure at $8.2 billion for Q1 2026.

  • On a quarterly basis, Receivables rose 12.05% to $8.2 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $8.2 billion, a 12.05% increase, with the full-year FY2025 number at $7.9 billion, up 14.5% from a year prior.
  • Receivables hit $8.2 billion in Q1 2026 for Abbott Laboratories, up from $7.9 billion in the prior quarter.
  • Over the last five years, Receivables for ABT hit a ceiling of $8.2 billion in Q1 2026 and a floor of $6.0 billion in Q1 2023.
  • Historically, Receivables has averaged $7.0 billion across 5 years, with a median of $6.9 billion in 2024.
  • Biggest five-year swings in Receivables: increased 17.77% in 2022 and later dropped 16.14% in 2023.
  • Tracing ABT's Receivables over 5 years: stood at $6.2 billion in 2022, then rose by 5.58% to $6.6 billion in 2023, then increased by 5.48% to $6.9 billion in 2024, then rose by 14.5% to $7.9 billion in 2025, then rose by 3.54% to $8.2 billion in 2026.
  • Business Quant data shows Receivables for ABT at $8.2 billion in Q1 2026, $7.9 billion in Q4 2025, and $8.1 billion in Q3 2025.